TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00728949
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 25 mg, oral
Study: NCT00728949
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly 250 mg, intramuscularly
Study: NCT00989352
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 110 mg/m² p.o., max. 3 times
Study: NCT00989352
Drug: Procarbazine
Normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
Study: NCT00989352
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m² i.v., max. 10 times
Study: NCT01828112
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib was the investigational treatment and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
Study: NCT01828112
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m\^2 every 21 days.
Study: NCT01828112
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m\^2 every 21 days.
Study: NCT03951337
Drug: 64Cu-ATSM
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 Cu-ATSM PET/CT scan
Study: NCT01544283
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
Study: NCT01890473
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00684099
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
Study: NCT00684099
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
Study: NCT00936156
Drug: Chemotherapy (carboplatin, etoposide, thiotepa)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
Study: NCT00983437
Drug: Armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01543958
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
Study: NCT01945281
Drug: Caspofungin
Normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01945281
Drug: Amphotericin B Deoxycholate
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00934089
Drug: PF-04217329
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular solution, once-daily for 14 days
Study: NCT00934089
Drug: latanoprost vehicle
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical ocular solution, once-daily for 14 days
Study: NCT00934089
Drug: latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical ocular solution, once-daily for 14 days
Study: NCT00003473
Drug: Atengenal
Normalized name: ATENGENAL
DrugBank: Antineoplaston A10 (DB11702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00003473
Drug: Astugenal
Normalized name: ASTUGENAL COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00001221
Drug: Growth Hormone (Humatrope)
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02521493
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM or IV
Study: NCT00864864
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
Study: NCT00049192
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02521493
Drug: Asparaginase Erwinia chrysanthemi
Normalized name: Asparaginase Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM or IV
Study: NCT02521493
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and IV
Study: NCT02521493
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02521493
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02521493
Drug: Mitoxantrone Hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02521493
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01112358
Drug: Analogous GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analogous GnRH antagonist will be administered as specified in the arm description.
Study: NCT01112358
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone will be administered as specified in the arm description.
Study: NCT03179345
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03179345
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01337700
Drug: Milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
Study: NCT01140893
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time.
Study: NCT00424489
Drug: ATG (rabbit)
Normalized name: ATGAM
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00424489
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00424489
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00424489
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02090829
Drug: Syntocinon (synthetic oxytocin)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
Study: NCT03868709
Drug: Penehyclidine inhalation
Normalized name: Penequinine, Penehyclidine
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
Study: NCT03783208
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
Study: NCT00802802
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
Study: NCT00802802
Drug: Rifampin-containing anti-TB therapy
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
Study: NCT01166542
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
Study: NCT01166542
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
Study: NCT02582970
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
Study: NCT02582970
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
Study: NCT02582970
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
Study: NCT02582970
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
Study: NCT00003237
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003237
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01188928
Drug: Calcipotriol plus betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical suspension once daily for up to 8 weeks.
Study: NCT01188928
Drug: Betamethasone-17,21-dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical suspension once daily for up to 8 weeks.
Study: NCT01188928
Drug: Calcipotriene
Normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical suspension once daily for up to 8 weeks.
Study: NCT01188928
Drug: Topical suspension vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical suspension once daily for up to 8 weeks.
Study: NCT03552757
Drug: Semaglutide 1.0 mg
Normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
Study: NCT03552757
Drug: Semaglutide 2.4 mg
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
Study: NCT03298451
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab IV (intravenous infusion).
Study: NCT01431924
Drug: Higher-dose inhaled corticosteroids
Normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone propionate 110 or 220 mcg
Study: NCT01431924
Drug: Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
Study: NCT02570074
Drug: Fosfomycin
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad spectrum antibiotic
Study: NCT03298451
Drug: Tremelimumab (Regimen 1)
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab IV (intravenous infusion).
Study: NCT03298451
Drug: Tremelimumab (Regimen 2)
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab IV (intravenous infusion).
Study: NCT03298451
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib, as per standard of care
Study: NCT03298451
Drug: Durvalumab (Regimen 2)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab IV (intravenous infusion).
Study: NCT00926328
Drug: Triclosan, fluoride
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six Month study, brush twice daily
Study: NCT00926328
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily usage
Study: NCT00639678
Drug: raxibacumab
Normalized name: Raxibacumab
DrugBank: Raxibacumab (DB08902)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 1
Study: NCT03502668
Drug: ASTX727 LD
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral decitabine (LD) + cedazuridine (E7727)
Study: NCT03502668
Drug: ASTX727 SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral decitabine (SD) + cedazuridine (E7727)
Study: NCT03765632
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan is used for non-myeloablative conditioning
Study: NCT03765632
Drug: Peg-Ada
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study: NCT00639678
Drug: raxibacumab
Normalized name: Raxibacumab
DrugBank: Raxibacumab (DB08902)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg/kg intravenously, single dose, day 0, Group 2
Study: NCT04410328
Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
Study: NCT01307098
Drug: Sebelipase alfa 0.35 mg/kg
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study: NCT01307098
Drug: Sebelipase alfa 1 mg/kg
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study: NCT01988883
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
Study: NCT01988883
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
Study: NCT01307098
Drug: Sebelipase alfa 3 mg/kg
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study: NCT00982553
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800mg once daily
Study: NCT00982553
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg twice daily
Study: NCT00903396
Drug: palonosetron hydrochloride
Normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03119831
Drug: Alcohol-based Chlorhexidine Gluconate 0.12%
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study: NCT03119831
Drug: Alcohol-free Chlorhexidine Gluconate 0.12%
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study: NCT03119831
Drug: C31G
Normalized name: C31G
DrugBank: C31G (DB05398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study: NCT04590235
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available.
Study: NCT04308681
Drug: BMS-986278
Normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT02070549
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02304679
Drug: 1 month of PDE5i treatment
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg Tadalafil per day for 1 month
Study: NCT03295721
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl without epinephrine, 50 mg by injection
Study: NCT01920737
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
Study: NCT01520051
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 monthly intravenous infusions of 750 mg
Study: NCT01920737
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01920737
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no